Haemonetics (HAE) Invested Capital (2010 - 2026)

Haemonetics has reported Invested Capital for 17 years, with the latest figure at $2.0 billion in Q2 2026.

• On a quarterly basis, Invested Capital fell 15.79% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 15.79% decrease from a year earlier, with the FY2026 full-year figure at $2.0 billion, down 1.21% from the prior year.
• Invested Capital was $2.0 billion for Q2 2026 at Haemonetics, roughly flat from $2.0 billion in the prior quarter.
• The five-year high for Invested Capital was $2.4 billion in Q4 2025, with the low at $1.5 billion in Q1 2022.
• Average Invested Capital over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Invested Capital surged 46.56% in 2022, then slipped 15.79% in 2026.
• Over 5 years, Invested Capital stood at $1.5 billion in 2022, then grew by 17.58% to $1.8 billion in 2023, then rose by 17.52% to $2.1 billion in 2024, then gained by 14.51% to $2.4 billion in 2025, then slipped by 16.82% to $2.0 billion in 2026.
• The last three Invested Capital figures came in at $2.0 billion (Q2 2026), $2.0 billion (Q1 2026), and $2.4 billion (Q4 2025), per Business Quant data.